Actively Recruiting
DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
Led by Second Affiliated Hospital of Guangzhou Medical University · Updated on 2025-02-20
130
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
Sponsors
S
Second Affiliated Hospital of Guangzhou Medical University
Lead Sponsor
Z
Zhongshan People's Hospital, Guangdong, China
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization with drug-eluting beads (DEB-TACE) combined with hepatic artery infusion chemotherapy (HAIC) with oxaliplatin and raltitrexed (RALOX-HAIC) versus DEB-TACE alone for unresectable large hepatocellular carcinoma (HCC).
CONDITIONS
Official Title
DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed hepatocellular carcinoma by histology, cytology, or clinical diagnosis
- At least one measurable tumor inside the liver
- Largest tumor size greater than 7 cm
- Tumor recurrence allowed after curative treatments like surgery or ablation
- Child-Pugh liver function score between 5 and 7
- ECOG performance status of 0 or 1
- Adequate blood cell counts and organ function (specified platelet, leukocyte, neutrophil counts, liver enzymes, kidney function, and prothrombin time limits)
You will not qualify if you...
- Presence of major blood vessel invasion or cancer spread outside the liver
- Diffuse hepatocellular carcinoma
- Decompensated liver disease including ascites, bleeding from varices, or hepatic encephalopathy
- Previous palliative treatments such as TACE, arterial embolization, HAIC, radiation, or systemic therapy
- Heart or kidney dysfunction preventing TACE or HAIC
- History of other cancers
- Uncontrolled infections
- History of HIV infection
- Recent or severe gastrointestinal bleeding
- History of organ or cell transplantation
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China, 510260
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here